News Archives

Back by popular demand this year are APMA’s Surgical Blitz sessions, featuring multiple, short presentations on a variety of topics, with practical advice perfect for every foot and ankle surgeon.

The National is truly the must-attend event for every podiatrist, covering the entire spectrum of foot and ankle care and representing every voice in podiatric medicine and surgery.

Most podiatric physicians know exactly how to handle a patient with heel pain, from diagnosis to treatment options. But a patient who is angry about the office running late, or one who can’t seem to follow doctor’s orders can be a significantly larger challenge.

Ross Taubman, DPM, never could have foreseen the path his career would take. “You don’t set out as a child saying, I’m going to be the president of an insurance company one day!”

In a continued effort to foster inclusivity and promote diversity within the profession, APMA invites all attendees to join us for the Diversity, Equity, and Inclusion (DEI) reception.

Aetna has informed APMA that effective July 23, it will drop its external review program regarding use of -59 Modifier when submitted with CPT 11719-11721, G0127, and 11055-11057.

As of June 27, all new DEA license applications and DEA licensure renewals will now require an attestation that the applicant has completed eight hours “on the treatment and management of patients with opioid or other substance use disorders.”

APMA submitted two comment letters to CMS on Monday, July 3, in responses to proposed changes to Medicaid generally and Medicaid Managed Care.

APMA’s Center for Professional Advocacy is now welcoming applications from state components for the 2023 State Advocacy Forum and a virtual mini summit on Physician Extenders.

On Thursday, APMA will meet with CMS to revisit its surgical nails treatment policy, establishing use parameters for CPT® 111730 and 11732.

APMA is pleased to announce that the 2022 Spring Virtual Coding Seminar is now available on demand for a registration fee of $99.50! Originally held on April 22, the seminar presents four hours of education on a variety of coding topics presented by Jeffrey Lehrman, DPM.

Our opening session at The National is not to be missed! On Thursday, July 13, Ross Taubman, DPM, president and chief medical officer for PICA, will deliver the opening address “Servant Leadership—Life is Not a Linear Path.”

APMA submitted comments to the US Department of Education (USDE) on June 20, in response to a recently released USDE proposed rule that would require institutions to “provide students with geographically accessible clinical, or externship opportunities related to and required for completion of the credential or licensure in a recognized occupation within 45 days of the successful completion of other required coursework,” in order to begin and continue to participate in any Title IV or Higher Education Act program.

APMA presented oral testimony to HHS' Interdepartmental Substance Use Disorders Coordinating Committee (ISUDCC) on June 5, requesting that APMA and CPME be approved as a provider and accrediting entity, respectively, for the new DEA MATE Act requirements.

Effective July 1, providers and suppliers are required to report the JZ modifier on all claims that bill for drugs and biologicals from single-dose containers that are separately payable under Medicare Part B when there are no discarded amounts.

Registration for the 2023 State Advocacy Forum will open soon! We ask that all state components and societies share the application provided here with their young physician members and encourage them to apply by the May 31 deadline.

APMA joined with AMA and other specialty medical societies to submit a comment letter regarding Cigna’s modifier 25 policy.

Last week, APMA submitted formal comments to the Substance Abuse and Mental Health Services Administration (SAMHSA), expressing our ongoing concerns related to the DEA MATE Act, and following up our meeting on April 28.

The implementation date for the revised fellowship documents, CPME 820 and 830, is July 1.

The DEA recently released a temporary rule extending COVID-19 telehealth flexibilities for the prescription of controlled substances.